Last reviewed · How we verify

Inhalation Sedation

Moscow Regional Research and Clinical Institute (MONIKI) · FDA-approved active Small molecule Quality 5/100

Inhalation Sedation, marketed by the Moscow Regional Research and Clinical Institute (MONIKI), holds a niche position in the sedation market. The drug's key strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameInhalation Sedation
SponsorMoscow Regional Research and Clinical Institute (MONIKI)
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: